Study for BRAFV600E Mutant Metastatic Colorectal Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body and cannot be removed by surgery.
- Your tumor has a gene change called BRAFV600E, confirmed by a lab test.
- You do not have a history of long-term inflammatory bowel disease, chronic diarrhea, or repeated bowel blockages.
- You do not have brain tumors causing symptoms.
- You do not have a serious active infection that needs treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
This trial tests cetuximab combined with dabrafenib and tislelizumab in people with advanced colorectal cancer that has a BRAF V600E mutation. It’s for cases where the first standard treatment didn’t work or couldn’t be tolerated, aiming to shrink tumors and improve control of the disease.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.